Published in Curr Drug Metab on October 01, 2011
Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2. Proc Natl Acad Sci U S A (2013) 0.96
Overlapping substrate and inhibitor specificity of human and murine ABCG2. Drug Metab Dispos (2013) 0.88
Using positron emission tomography to study transporter-mediated drug-drug interactions in tissues. Clin Pharmacol Ther (2014) 0.86
Alzheimer's and ABC transporters--new opportunities for diagnostics and treatment. Neurobiol Dis (2014) 0.85
Organic anion-transporting polypeptides. Curr Top Membr (2014) 0.84
Factors that limit positron emission tomography imaging of p-glycoprotein density at the blood-brain barrier. Mol Pharm (2013) 0.82
Synthesis and preclinical evaluation of the radiolabeled P-glycoprotein inhibitor [(11)C]MC113. Nucl Med Biol (2012) 0.81
Advances in PET imaging of P-glycoprotein function at the blood-brain barrier. ACS Chem Neurosci (2012) 0.79
The antiepileptic drug mephobarbital is not transported by P-glycoprotein or multidrug resistance protein 1 at the blood-brain barrier: a positron emission tomography study. Epilepsy Res (2012) 0.79
Regulation of ABC transporters at the blood-brain barrier. Clin Pharmacol Ther (2015) 0.79
Molecular Imaging of Membrane Transporters' Activity in Cancer: a Picture is Worth a Thousand Tubes. AAPS J (2015) 0.79
Pharmacokinetic modeling of P-glycoprotein function at the rat and human blood-brain barriers studied with (R)-[11C]verapamil positron emission tomography. EJNMMI Res (2012) 0.79
Interaction of HM30181 with P-glycoprotein at the murine blood-brain barrier assessed with positron emission tomography. Eur J Pharmacol (2012) 0.78
Role of (drug) transporters in imaging in health and disease. Drug Metab Dispos (2014) 0.76
Tariquidar Is an Inhibitor and Not a Substrate of Human and Mouse P-glycoprotein. Drug Metab Dispos (2015) 0.75
Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer (2002) 15.72
Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab (2007) 11.79
Targeting multidrug resistance in cancer. Nat Rev Drug Discov (2006) 10.55
Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (1992) 8.84
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta (1976) 7.41
A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst (2000) 3.98
P-glycoprotein: from genomics to mechanism. Oncogene (2003) 3.66
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci U S A (1997) 3.20
Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci (2005) 3.19
Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene (2003) 3.12
Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther (2001) 2.67
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther (2002) 2.60
Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol (2005) 2.54
Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta (2007) 2.45
Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol (2005) 2.43
Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther (2005) 2.35
Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res (2000) 2.32
PET radiotracers: crossing the blood-brain barrier and surviving metabolism. Trends Pharmacol Sci (2009) 2.32
Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther (2007) 2.11
ABCG2: a perspective. Adv Drug Deliv Rev (2008) 1.97
Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm Res (2008) 1.93
From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci (2001) 1.89
The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol (1999) 1.84
Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther (2009) 1.77
P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin Cancer Res (2007) 1.74
Evaluation of tracer kinetic models for quantification of P-glycoprotein function using (R)-[11C]verapamil and PET. J Cereb Blood Flow Metab (2006) 1.68
ABCG2: structure, function and role in drug response. Expert Opin Drug Metab Toxicol (2008) 1.65
Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother (2004) 1.64
P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide. J Nucl Med (2010) 1.62
A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET. J Nucl Med (2009) 1.56
Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil. Epilepsia (2007) 1.55
P-glycoprotein function at the blood-brain barrier imaged using 11C-N-desmethyl-loperamide in monkeys. J Nucl Med (2008) 1.53
Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. J Pharmacol Exp Ther (2010) 1.52
Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology (2008) 1.48
Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther (2000) 1.48
MDR1-P-glycoprotein (ABCB1)-mediated disposition of amyloid-β peptides: implications for the pathogenesis and therapy of Alzheimer's disease. Clin Pharmacol Ther (2010) 1.47
The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). ACS Chem Neurosci (2010) 1.46
Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res (2009) 1.46
Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat. Nucl Med Biol (2005) 1.44
Application of microdialysis to clinical pharmacokinetics in humans. Clin Pharmacol Ther (1995) 1.44
Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET. J Nucl Med (2008) 1.44
Synthesis and evaluation of [N-methyl-11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function. J Med Chem (2008) 1.43
11C-loperamide and its N-desmethyl radiometabolite are avid substrates for brain permeability-glycoprotein efflux. J Nucl Med (2008) 1.37
ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier. J Neurochem (2008) 1.32
Positron emission tomography quantification of [(11)C]-DASB binding to the human serotonin transporter: modeling strategies. J Cereb Blood Flow Metab (2001) 1.32
Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J Clin Invest (2000) 1.32
Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration. Neurobiol Aging (2008) 1.30
Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration. Br J Clin Pharmacol (1984) 1.30
5-HT1A receptor binding and intracerebral activity in temporal lobe epilepsy: an [18F]MPPF-PET study. Brain (2004) 1.29
Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacol (1998) 1.28
Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans. J Nucl Med (2009) 1.27
Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar. J Med Chem (2009) 1.25
Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. J Neural Transm (Vienna) (2008) 1.25
Peripheral metabolism of (R)-[11C]verapamil in epilepsy patients. Eur J Nucl Med Mol Imaging (2007) 1.25
Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET. Eur J Nucl Med Mol Imaging (2009) 1.23
Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor. Bioorg Med Chem (2010) 1.20
Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans. Clin Pharmacol Ther (2005) 1.19
In vivo evaluation of P-glycoprotein function at the blood-brain barrier in nonhuman primates using [11C]verapamil. J Pharmacol Exp Ther (2005) 1.19
Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clin Pharmacol Ther (2006) 1.18
Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia (2006) 1.17
Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET. Neuroimage (2006) 1.17
Fluoro-, bromo-, and iodopaclitaxel derivatives: synthesis and biological evaluation. Nucl Med Biol (2003) 1.17
Biodistribution, radiation dose estimates, and in vivo Pgp modulation studies of 18F-paclitaxel in nonhuman primates. J Nucl Med (2003) 1.16
Synthesis and evaluation of [11C]XR9576 to assess the function of drug efflux transporters using PET. Ann Nucl Med (2010) 1.16
A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clin Cancer Res (2009) 1.15
Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil. J Nucl Med (2006) 1.15
Effect of a P-glycoprotein inhibitor, Cyclosporin A, on the disposition in rodent brain and blood of the 5-HT1A receptor radioligand, [11C](R)-(-)-RWAY. Synapse (2007) 1.15
Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J Pharmacol Exp Ther (2003) 1.14
Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. Anticancer Drugs (1997) 1.13
Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds. Drug Metab Dispos (2008) 1.13
Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [11C]verapamil measured with PET. Neuroimage (2003) 1.13
Quantitative analysis of 11C-verapamil transfer at the human blood-brain barrier for evaluation of P-glycoprotein function. J Nucl Med (2006) 1.12
(R)- and (S)-[11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation. Nucl Med Biol (2003) 1.11
Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel. J Nucl Med (2005) 1.11
Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. Clin Cancer Res (2003) 1.11
In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically. J Nucl Med (2007) 1.09
Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier. J Med Chem (2009) 1.09
Positron-emitting radioligands for studies in vivo-probes for human psychopharmacology. J Psychopharmacol (1993) 1.08
Regional P-glycoprotein activity and inhibition at the human blood-brain barrier as imaged by positron emission tomography. Clin Pharmacol Ther (2010) 1.08
Drug binding sites on P-glycoprotein are altered by ATP binding prior to nucleotide hydrolysis. Biochemistry (2000) 1.06
Evaluation of limiting brain penetration related to P-glycoprotein and breast cancer resistance protein using [(11)C]GF120918 by PET in mice. Mol Imaging Biol (2011) 1.06
A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res (2010) 1.04
Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET. Proc Natl Acad Sci U S A (2011) 1.03
Evaluation of [11C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats. Nucl Med Biol (2009) 1.02
Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of (99m)Tc-tetrofosmin. Biochem Pharmacol (2000) 1.02
Age dependency of cerebral P-gp function measured with (R)-[11C]verapamil and PET. Eur J Clin Pharmacol (2009) 1.01
Resistance to antiepileptic drugs and expression of P-glycoprotein in two rat models of status epilepticus. Epilepsy Res (2008) 1.01
Quantitative membrane protein expression at the blood-brain barrier of adult and younger cynomolgus monkeys. J Pharm Sci (2011) 1.00
Influence of P-glycoprotein on brain uptake of [18F]MPPF in rats. Eur J Pharmacol (2000) 0.99
In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats. Epilepsia (2001) 0.99
Pharmacokinetic assessment of multiple ATP-binding cassette transporters: the power of combination knockout mice. Mol Interv (2009) 0.99
Imaging multidrug resistance P-glycoprotein transport function using microPET with technetium-94m-sestamibi. Mol Imaging (2005) 0.98
N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier. Drug Metab Dispos (2010) 0.98
Brain radioligands--state of the art and new trends. Q J Nucl Med (2001) 0.97
Approaches using molecular imaging technology -- use of PET in clinical microdose studies. Adv Drug Deliv Rev (2010) 0.97
Investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) on pharmacokinetics and central nervous system penetration of abacavir and zidovudine in the mouse. Drug Metab Dispos (2008) 0.96
A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res (1999) 0.96
Assessment of regional differences in tariquidar-induced P-glycoprotein modulation at the human blood-brain barrier. J Cereb Blood Flow Metab (2009) 0.96
In vivo imaging of baboon and human dopamine transporters by positron emission tomography using [11C]WIN 35,428. Synapse (1993) 0.95
P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study. Lancet Neurol (2013) 1.82
A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET. J Nucl Med (2009) 1.56
Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET. J Nucl Med (2008) 1.44
Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. Bioorg Med Chem (2004) 1.35
Blood-brain barrier P-glycoprotein function in Alzheimer's disease. Brain (2011) 1.33
Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data. Clin Pharmacol Ther (2011) 1.33
Peripheral metabolism of (R)-[11C]verapamil in epilepsy patients. Eur J Nucl Med Mol Imaging (2007) 1.25
Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET. Eur J Nucl Med Mol Imaging (2009) 1.23
Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor. Bioorg Med Chem (2010) 1.20
Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans. Clin Pharmacol Ther (2005) 1.19
Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier. J Med Chem (2009) 1.09
Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake. Clin Cancer Res (2011) 1.06
Limitations of small animal PET imaging with [18F]FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease. Mol Imaging Biol (2009) 1.06
Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure-activity relationship. Biochem Pharmacol (2005) 1.04
A novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrier. J Neurosci (2011) 1.02
Age dependency of cerebral P-gp function measured with (R)-[11C]verapamil and PET. Eur J Clin Pharmacol (2009) 1.01
Pros and cons of using resazurin staining for quantification of viable Staphylococcus aureus biofilms in a screening assay. J Microbiol Methods (2009) 0.99
Synthesis of novel curcumin analogues and their evaluation as selective cyclooxygenase-1 (COX-1) inhibitors. Chem Pharm Bull (Tokyo) (2007) 0.98
Approaches using molecular imaging technology -- use of PET in clinical microdose studies. Adv Drug Deliv Rev (2010) 0.97
Synthesis of new acridone derivatives, inhibitors of NS3 helicase, which efficiently and specifically inhibit subgenomic HCV replication. J Med Chem (2010) 0.96
Development of a liquid chromatography method for the determination of linezolid and its application to in vitro and human microdialysis samples. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 0.96
Microdialysis versus other techniques for the clinical assessment of in vivo tissue drug distribution. AAPS J (2006) 0.96
Assessment of regional differences in tariquidar-induced P-glycoprotein modulation at the human blood-brain barrier. J Cereb Blood Flow Metab (2009) 0.96
Resveratrol blocks Akt activation in angiotensin II- or EGF-stimulated vascular smooth muscle cells in a redox-independent manner. Cardiovasc Res (2010) 0.94
Interaction of 11C-tariquidar and 11C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier. J Nucl Med (2013) 0.94
(R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP. Nucl Med Biol (2013) 0.93
A novel PET protocol for visualization of breast cancer resistance protein function at the blood-brain barrier. J Cereb Blood Flow Metab (2012) 0.91
The exploration of thienothiazines as selective butyrylcholinesterase inhibitors. Eur J Pharm Sci (2012) 0.90
No evidence for modulation of endothelial nitric oxide synthase by the olive oil polyphenol hydroxytyrosol in human endothelial cells. Atherosclerosis (2007) 0.89
Antioxidant activity of resveratrol, piceatannol and 3,3',4,4',5,5'-hexahydroxy-trans-stilbene in three leukemia cell lines. Oncol Rep (2006) 0.88
A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease. Clin Pharmacol Ther (2006) 0.87
Tariquidar and elacridar are dose-dependently transported by P-glycoprotein and Bcrp at the blood-brain barrier: a small-animal positron emission tomography and in vitro study. Drug Metab Dispos (2013) 0.86
Positron emission tomography for use in microdosing studies. Curr Opin Drug Discov Devel (2008) 0.86
A novel prodrug-based strategy to increase effects of bumetanide in epilepsy. Ann Neurol (2014) 0.85
Radiosynthesis and in vivo evaluation of 1-[18F]fluoroelacridar as a positron emission tomography tracer for P-glycoprotein and breast cancer resistance protein. Bioorg Med Chem (2011) 0.85
A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer. Eur J Nucl Med Mol Imaging (2011) 0.84
Novel resveratrol analogs induce apoptosis and cause cell cycle arrest in HT29 human colon cancer cells: inhibition of ribonucleotide reductase activity. Oncol Rep (2008) 0.83
A combined accelerator mass spectrometry-positron emission tomography human microdose study with 14C- and 11C-labelled verapamil. Clin Pharmacokinet (2011) 0.83
Benzanilides with spasmolytic activity: chemistry, pharmacology, and SAR. Bioorg Med Chem (2008) 0.83
Novel resveratrol derivatives induce apoptosis and cause cell cycle arrest in prostate cancer cell lines. Anticancer Res (2007) 0.83
[18F]Ciprofloxacin, a new positron emission tomography tracer for noninvasive assessment of the tissue distribution and pharmacokinetics of ciprofloxacin in humans. Antimicrob Agents Chemother (2004) 0.82
Synergistic action of resveratrol, an ingredient of wine, with Ara-C and tiazofurin in HL-60 human promyelocytic leukemia cells. Exp Hematol (2005) 0.82
Factors that limit positron emission tomography imaging of p-glycoprotein density at the blood-brain barrier. Mol Pharm (2013) 0.82
Antitumor effects of KITC, a new resveratrol derivative, in AsPC-1 and BxPC-3 human pancreatic carcinoma cells. Invest New Drugs (2008) 0.82
Clustering and filtering tandem mass spectra acquired in data-independent mode. J Am Soc Mass Spectrom (2013) 0.82
Radioligands targeting P-glycoprotein and other drug efflux proteins at the blood-brain barrier. J Labelled Comp Radiopharm (2013) 0.81
Biological evaluation of 2'-[18F]fluoroflumazenil ([18F]FFMZ), a potential GABA receptor ligand for PET. Nucl Med Biol (2004) 0.81
Cytotoxic and biochemical effects of 3,3',4,4',5,5'-hexahydroxystilbene, a novel resveratrol analog in HL-60 human promyelocytic leukemia cells. Exp Hematol (2006) 0.81
Synthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoate. Nucl Med Biol (2010) 0.81
Synthesis and preclinical evaluation of the radiolabeled P-glycoprotein inhibitor [(11)C]MC113. Nucl Med Biol (2012) 0.81
New ultrasensitive detection technologies and techniques for use in microdosing studies. Bioanalysis (2009) 0.81
Microdosing studies in humans: the role of positron emission tomography. Drugs R D (2008) 0.81
Stilbene analogues affect cell cycle progression and apoptosis independently of each other in an MCF-7 array of clones with distinct genetic and chemoresistant backgrounds. Oncol Rep (2008) 0.80
GABAA receptor modulation by piperine and a non-TRPV1 activating derivative. Biochem Pharmacol (2013) 0.80
Assessment of cerebral P-glycoprotein expression and function with PET by combined [11C]inhibitor and [11C]substrate scans in rats. Nucl Med Biol (2013) 0.80
Polymorphism of the beta-2 adrenoceptor and IOP lowering potency of topical timolol in healthy subjects. Mol Vis (2005) 0.80
Imaging of P-glycoprotein function and expression to elucidate mechanisms of pharmacoresistance in epilepsy. Curr Top Med Chem (2010) 0.79
Pharmacokinetic modeling of P-glycoprotein function at the rat and human blood-brain barriers studied with (R)-[11C]verapamil positron emission tomography. EJNMMI Res (2012) 0.79
The antiepileptic drug mephobarbital is not transported by P-glycoprotein or multidrug resistance protein 1 at the blood-brain barrier: a positron emission tomography study. Epilepsy Res (2012) 0.79
Synthesis and pharmacological profile of non-peptide vasopressin antagonists. Eur J Pharm Sci (2005) 0.79
Foam cell specific LXRα ligand. PLoS One (2013) 0.78
Positron emission tomographic evaluation of the putative dopamine-D3 receptor ligand, [11C]RGH-1756 in the monkey brain. Neurochem Int (2004) 0.78
Testicular sperm extraction in azoospermic patients with gonadal germ cell tumors prior to chemotherapy--a new therapy option. Asian J Androl (2002) 0.78
Interaction of HM30181 with P-glycoprotein at the murine blood-brain barrier assessed with positron emission tomography. Eur J Pharmacol (2012) 0.78
Radiosynthesis and assessment of ocular pharmacokinetics of (124)I-labeled chitosan in rabbits using small-animal PET. Mol Imaging Biol (2011) 0.78
Using structural and mechanistic information to design novel inhibitors/substrates of P-glycoprotein. Curr Top Med Chem (2010) 0.78
Impact of hormonal therapy on the detection of promoter hypermethylation of the detoxifying glutathione-S-transferase P1 gene (GSTP1) in prostate cancer. BMC Urol (2006) 0.77
'Bridged' stilbene derivatives as selective cyclooxygenase-1 inhibitors. Bioorg Med Chem (2007) 0.77
A novel electrophilic synthesis and evaluation of medium specific radioactivity (1R,2S)-4-[18F]fluorometaraminol, a tracer for the assessment of cardiac sympathetic nerve integrity with PET. Nucl Med Biol (2004) 0.77
Comparison of three different purification methods for the routine preparation of [11C] Metomidate. Appl Radiat Isot (2003) 0.76
Synthesis, spasmolytic activity and structure-activity relationship study of a series of polypharmacological thiobenzanilides. Eur J Pharm Sci (2010) 0.76
Efficient modulation of γ-aminobutyric acid type A receptors by piperine derivatives. J Med Chem (2014) 0.76
A journey from benzanilides to dithiobenzanilides: Synthesis of selective spasmolytic compounds. Bioorg Med Chem (2010) 0.76
Identification and characterization of diarylimidazoles as hybrid inhibitors of butyrylcholinesterase and amyloid beta fibril formation. Eur J Pharm Sci (2011) 0.76
[18F]FE@SUPPY: a suitable PET tracer for the adenosine A3 receptor? An in vivo study in rodents. Eur J Nucl Med Mol Imaging (2015) 0.75
Cardiovascular flashlight. Tuberculous pericarditis with constrictive physiology. Eur Heart J (2009) 0.75
Synthesis and biological activity of thienodiltiazem in isolated heart muscle preparations of guinea pigs. Arzneimittelforschung (2007) 0.75
SAR-guided development and characterization of a potent antitumor compound toward B-cell neoplasms with no detectable cytotoxicity toward healthy cells. J Med Chem (2015) 0.75
Synthesis and multidrug-resistance modulating activity of a series of thienothiazines. Arch Pharm (Weinheim) (2002) 0.75
Effects of novel synthesized pyridothiazines on various guinea pig heart muscle preparations. Biol Pharm Bull (2004) 0.75
Studies on the chemistry of thienoanellated O,N- and S,N-containing heterocycles. Part 30: synthesis and pharmacological properties of thieno[2,3-b][1,4]thiazines with potential vasopressin receptor antagonistic activity. Bioorg Med Chem (2005) 0.75
Receptor gene messenger RNA expression in metastatic lesions of prostate cancer. J Urol (2002) 0.75
Technical solution for data collection, data safety and data privacy legislation: experiences from the SWEET study. Pediatr Diabetes (2012) 0.75
Cyclooxygenase-1 and cyclooxygenase-2 inhibition of novel 1,2-disubstituted imidazoles. Arch Pharm (Weinheim) (2005) 0.75